Schluger NW, Burman WJ, Gallicano K, Peloquin C

Idioma: Español
Referencias bibliográficas: 158
Paginas: 149-156
Archivo PDF: 102.53 Kb.

FRAGMENTO

Se estima que en el mundo existen 14 a 15 millones de personas infectadas con el VIH y que cerca de seis millones de esas personas también lo están con Mycobacterium tuberculosis.

REFERENCIAS (EN ESTE ARTÍCULO)

1. Shafer RW, Edlin BR. Tuberculosis in patients infected with human immunodeficiency virus: perspective on the past decade. Clin Infect Dis 1996;22:683-704.

2. Raviglione MC, Snider DE Jr., Kochi A. Global epidemiology of tuberculosis. Morbidity and mortality of a worldwide epidemic. JAMA 1995;273:220-6.

3. Goletti D, Weissman D, Jackson RW, et al. Effect of Mycobacterium tuberculosis in HIV replication. Role of immune activation. J Immunol 1996;157:1271-8.

4. Nakata K, Rom WN, Honda Y, et al. Mycobacterium tuberculosis enhances human immundeficiency virus-1 replication in the lung. Am J Respir Crit Care Med 1997;155:996-1003.

5. Zhang Y, Nakata K, Weiden M, Rom WN. Mycobacterium tuberculosis enhances human immunodeficiency virus-1 replication by transcriptional activation at the lung terminal repeat. J Clin Invest 1995;95:2324-31.

6. Whalen C, Horsburgh CR, Hom D, Lahart C, Simberkoff M, Ellner J. Accelerated course of human immunodeficiency virus infection after tuberculosis. Am J Respir Crit Care Med 1995;151:129-35.

7. Park MM, Davis AL, Schluger NW, Cohen H, Rom WN. Outcome of MDR-TB patients, 1983-1993. Prolonged survival with appropriate therapy. Am J Respir Crit Care Med 1996;153:317- 24.

8. Fischl MA, Uttamchandani RB, Daikos GL, et al. An outbreak of tuberculosis caused by multiple-drug-resistant tubercle bacilli among patients with HIV infection. Ann Intern Med 1992;117:177- 83.

9. Brindle RJ, Nunn PP, Githui W, Allen BW, Gathua S, Waiyaki P. Quantitative bacillary response to treatment in HIV-associated pulmonary tuberculosis. Am Rev Respir Dis 1993;147:958-61.

10. Bass JB Jr., Farer LS, Hopewell PC, et al. Treatment of tuberculosis and tuberculosis infection in adults and children. American Thoracic Society and the Centers for Disease Control and Prevention. Am J Respir Crit Care Med 1994;149:1359- 74.

11. Perriens JH, St. Louis ME, Mukadi YB, et al. Pulmonary tuberculosis in HIV-infected patients in Zaire. A controlled trial of treatment for either 6 or 12 months. N Engl J Med 1995;332:779-84.

12. Kassim S, Sassan-Morokro M, Ackah A, et al. Two-year followup of persons with HIV-1 and HIV-2-associated pulmonary tuberculosis treated with short-course chemotherapy in West Africa. AIDS 1995;9:1185-91.

13. Chaisson RE, Clermont HC, Holt EA, et al. Six-month supervised intermittent tuberculosis therapy in Haitian patients with and without HIV infection. Am J Respir Crit Care Med 1996;154:1034-8.

14. El-Sadr WM, Perlman DC, Matts JP, et al. Evaluation of an intensive intermittent-induction regimen and duration of shortcourse treatment for human immunodeficiency virus-related pulmonary tuberculosis. Clin Infect Dis 1998;26:1148-58.

15. Brudney K, Dobkin J. Resurgent tuberculosis in New York City. Human immunodeficiency virus, homelessness, and the decline of tuberculosis control programs. Am Rev Respir Dis 1991;144:745-9.

16. Schluger N, Ciotoli C, Cohen D, Johnson H, Rom WN. Comprehensive tuberculosis control for patients at high risk for noncompliance. Am J Respir Crit Care Med 1995;151:1486-90.

17. Weis SE, Slocum PC, Blais FX, et al. The effect of directly observed therapy on the rates of drug resistance and relapse in tuberculosis. N Engl J Med 1994;330:1179-84.

18. Chaulk CP, Moore-Rice K, Rizzo R, Chaisson RE. Eleven years of community based directly observed therapy for tuberculosis. JAMA 1995;274:945-51.

19. Chaulk CP, Kazandjian VA. Directly observed therapy for treatment completion of pulmonary tuberculosis. Consensus Statement of the Public Health Tuberculosis Guidelines Panel. JAMA 1998;279:943-8.

20. Albert PL, Munsiff SS, Gourevith MN, Greenberg B, Klein RS. A prospective study of tuberculosis and human immunodeficiency virus infection: clinical manifestations and factors associated with survival. Clin Infect Dis 1997;24:661-8.

21. Whalen C, Horsburgh CR Jr., Hom D, Lahart C, Simberkoff M, Ellner J. Site of disease and opportunistic infection predict survival in HIV-associated tuberculosis. AIDS 1997;11:455-60.

22. Sirgel FA, Botha FJ, Parkin DP, et al. The early bactericidal activity of rifabutin in patients with pulmonary tuberculosis measured by sputum viable counts: a new method of drug assessment. J Antimicrob Chemother 1993;32:867-75.

23. González-Montaner LJ, Natal S, Yongchaiyud P, Olliaro P. Rifabutin for the treatment of newly diagnosed pulmonary tuberculosis: a multinational, randomized comparative study versus rifampicin. Rifabutin Study Group. Tuber Lung Dis 1994;75:341-7.

24. McGregor MM, Olliaro P, Wolmarans L, et al. Efficacy and safety of rifabutin in the treatment of patients with newly diagnosed pulmonary tuberculosis. Am J Respir Crit Care Med 1996;154:1462-7.

25. Schwander S, Rusch-Gerdes S, Mateega A, et al. A pilot study of antituberculosis combinations comparing rifabutin with rifampicin in the treatment of HIV-1 associated tuberculosis. A single-blind randomized evaluation in Ugandan patients with HIV-1 infection and pulmonary tuberculosis. Tuber Lung Dis 1995;76:210-8.

26. Report of the NIH Panel to Define Principles of Therapy of HIV Infection. MMWR 1998;47:1-41.

27. Guidelines for the use of antiretroviral agents in HIV-infected adults and adolescents. Department of Health and Human Services and Henry J. Kaiser Family Foundation. MMWR 1998;47:43-82.

28. Controlled trial of 6-month and 9-month regimens of daily and intermittent streptomycin plus isoniazid plus pyrazinamide for pulmonary tuberculosis in Hong Kong. The results up to 30 months. Am Rev Respir Dis 1997;115:727-35.

29. Controlled clinical trial comparing a 6-month and a 12-month regimen in the treatment of pulmonary tuberculosis in the Algerian Sahara. Algerian working group/British Medical Research Council cooperative study. Am Rev Respir Dis 1984;129:921-8.

30. Controlled clinical trial of four short-course (6 month) regimens of chemotherapy for treatment of pulmonary tuberculosis. Third report. East African-British Medical Research Councils. Lancet 1974;2:237-40.

31. Controlled clinical trial of four short-course regimens of chemotherapy for two durations in the treatment of pulmonary tuberculosis. Second report. Third East African/British Medical Research Council Study. Tubercle 1980;61:59-69.

32. Mohanty KC, Dhamgaye TM. Controlled trial of ciprofloxacin in short-term chemotherapy for pulmonary tuberculosis. Chest 1993;104:1194-8.

33. Perriens JH, colebunders RL, Karahunga C, et al. Increased mortality and tuberculosis treatment failure rate among human immunodeficiency virus (HIV) seropositive compared with HIV seronegative patients with pulmonary tuberculosis treated with “standard” chemotherapy in Kinshasa, Zaire. Am Rev Respir Dis 1991;144:750-5.

34. Elliott AM, Halwiindi B, Hayes RJ, et al. The impact of human immunodeficiency virus on response to treatment and recurrence rate in patients treated for tuberculosis two-year follow-up of a cohort in Lusaka, Zambia. J Trop Med Hyg 1995;98:9-21.

35. Hawken M, Nunn P, Gathua S, et al. Increased recurrence of tuberculosis in HIV-infected patients in Kenya. Lancet 1993;342:332-7.

36. Five-year follow-up of a controlled trial of five 6-month regimens of chemotherapy for pulmonary tuberculosis. Hong Kong Chest Service British Medical Research Council. Am Rev Respir Dis 1987;136:1339-42.

37. Ridzon R, Whitney CG, McKenna MT, et al. Risk factors for rifampim monoresistant tuberculosis. Am J Respir Crit Care Med 1998;157:1881-4.

38. Munsiff SS, Joseph S, Ebrahimzadeh A, Frieden TR. Rifampimmonoresistant tuberculosis in New York City, 1993-1994. Clin Infect Dis 1997;25:1465-7.

39. Controlled trial of 6- and 9-month regimens of daily and intermittent streptomycin plus isoniazid plus pyrazinamide for pulmonary tuberculosis in Hong Kong. Tubercle 1975;56:81- 96.

40. Bobrowitz ID. Comparison of ethambutol-INH versus INH-PAS in original treatment of pulmonary tuberculosis. Ann NY Acad Sci 1966;135:921-39.

41. Bobrowitz ID, Robins DE. Ethambutol-isoniazid versus PASisoniazid in original treatment of pulmonary tuberculosis. Am Rev Respir Dis 1967;96:428-38.

42. Bobrowitz ID. Ethambutol-isoniazid versus streptomycinethambutol- isoniazid in original treatment of cavitary tuberculosis. Am Rev Respir Dis 1974;109:548-53.

43. Turett GS, Telzak EE, Torian LV, et al. Improved outcomes for patients with multidrug-resistant tuberculosis. Clin Infect Dis 1995;21:1238-44.

44. Iseman MD. Treatment of multidrug-resistant tuberculosis. N Engl J Med 1993;329:784-91.

45. Kennedy N, Berger L, Curram J, et al. Randomized controlled trial of a drug regimen that includes ciprofloxacin for the treatment of pulmonary tuberculosis. Clin Infect Dis 1996;22:827- 33.

46. Holland SM, Eisenstein EM, Kuhns DB, et al. Treatment of refractory disseminated nontuberculous mycobacterial infection with interferon gamma. A preliminary report. N Engl J Med 1994;330:1348-55.

47. Condos R, Rom WN, Schluger NW. Treatment of multidrugresistant pulmonary tuberculosis with interferon gamma via aerosol. Lancet 1997;349:1513-5.

48. Tramontana JM, Utaipat U, Molloy A, et al. Thalidomide treatment reduces tumor necrosis factor alpha production and enhances weight gain in patients with pulmonary tuberculosis. Mol Med 1995;1:384-97.

49. Wallis RS, Nsubuga P, Whalen C, et al. Pentoxifylline therapy in human immunodeficiency virus-seropositive persons with tuberculosis: a randomized, controlled trial. J Infect Dis 1996;174:727-33.

50. Centers for Disease Control and Prevention. Reported tuberculosis cases in the United States, 1996. August 1997

51. Gulik RM, Mellors JW, Havlir D, et al. Treatment with indinavir, zidovudine, and lamivudine in adults with human immunodeficiency virus infection and prior antiretroviral therapy. N Engl J Med 1997;337:734-9.

52. Hammer SM, Squires KE, Hughes MD, et al. A controlled trial of two nucleoside analogues plus indinavir in persons with human immunodeficiency virus infection and CD4 cell counts of 200 per cubic millimeter of less. N Engl J Med 1997;337:725- 33.

53. CAESAR Coordinating Committee. Randomized trial of addition of lamivudine or lamivudine plus lovaride zidovudine-containing regimens for patients with HIV-1 infection: the CAESER trial. Lancet 1997;349:1413-21.

54. Palella F Jr, Delany K, Moorman A, et al. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. N Engl J Med 1998;338:853-60.

55. Engelhard D, Stutman HR, Marks MI. Interaction of ketoconazole with rifampicin and isoniazid N Engl J Med 1984;311:1681-3.

56. Drayton K, Dickinson G, Rinaldi MG. Coadministration of rifampin and itraconazole leads to undetectable levels of serum itraconazole. Clin Infect Dis 1994;18:266.

57. Tucker RM, Denning DW, Hanson LH, et al. Interaction of azoles with rifampin, phenytoin, and carbamazepine: in vitro and clinical observations. Clin Infec Dis 1992;14:165-74.

58. D’Arcy PF, McElnay JC, Welling PG. Mechanisms of drug interactions. Berlin: Springer-Verlag, 1996.

59. Rolan PE. Plasma protein binding displacement interactions – why are they still regarded as clinically important? Br J Clin Pharmacol 1994;37:125-8.

60. MacKichan JJ. Protein binding drug displacement interactions fact or fiction? Clin Pharmacokinet 1989;16:65-73.

61. Wright JD, Boudinot FD, Ujhelyi MR. Measurement and analysis of unbound drug concentration. Clin Pharmacokinet 1996;30:445-62.

62. Li AP, Reith MK, Rasmussen A, et al. Primary human hepatocytes as a tool for the evaluation of structure activity relationship in cytochrome P450 induction potential of xenobiotics: evaluation of rifampin, rifapentine, and rifabutin. Chem Biol Interact 1997;107:17-30.

63. Eagling VA, Back DJ, Barry MG. Differential inhibition of cytochrome P450 isoforms by the protease inhibitors, ritonavir, saquinavir, and indinavir. Br J Clin Pharmacol 1997;44:190-4.

64. von Moltke LL, Greenblatt DD, Grassi BW, et al. Protease inhibitors as inhibitors of human cytochrome P450: high risk associated with ritonavir. J Clin Pharmacol 1998;38:106-11.

65. Woolley J, Studenberg S, Boehlert C, Bowers G, Sinhababu A, Adams P. Cytochrome p-450 isozyme induction, inhibition, and metabolism studies with the HIV protease inhibitor, 141W94 [abstract no A-60]. In: Program and abstracts of the 37th Interscience Conference on Antimicrobial Agents and Chemotherapy. Washington, DC: American Society for Microbiology, 1997:12.

66. Decker CJ, Laitinen LM, Bridson GW, Raybuck SA, Tung RD, Chaturvedi PR. Metabolism of amprenavir in liver microsomes: role of CYP3A4 inhibition for drug interactions. J Pharm Sci 1998;87:803-7.

67. Cato A, Cavanaugh J, Shi H, Hsu A, Leonard J, Granneman GR. The effect of multiple doses of ritonavir on the pharmacokinetics of rifabutin. Clin Pharmacol Ther 1998;63:414- 21.

68. Ouellet D, Hsu A, Qian J, Locke CS, Cavanaugh J. Effect of ritonavir of the pharmacokinetics of ethinyl oestradiol in healthy female volunteers. Br J Clin Pharmacol 1998;46:111-6.

69. Kerr B, Lee C, Yuen G, et al. Overview of in-vitro and in-vivo drug interaction studies of nelfinavir mesylate, a new HIV-1 protease inhibitor [abstract no. 373]. In: Program and abstracts on the 4th Conference of Retroviruses and Opportunistic Infections. Washington, DC: Foundation for Retrovirology and Human Health, 1997:133.

70. Bertz RJ, Granneman GR. Use of in vitro and in vivo data to estimate the likelihood of metabolic pharmacokinetic interactions. Clin Pharmacokinet 1997;32:210-58.

71. Gallicano K, Sahai J, Foster B, Bouchard J, Cameron DW. Rifampin decreases zidovudine plasma concentrations in HIV infected patients [abstract n. 612]. In: Program and abstracts of the 4th Conference on Retroviruses and Opportunistic Infections. Washington, DC: Foundation for Retrovirology and Human Health, 1997:177.

72. O’Brien LW. Interactions and toxicities of drugs for HIV disease. The AIDS reader 1998;8:28-36.

73. Tseng AL, Foisy MM. Management of drug interactions in patients with HIV. Pharmacother 1997;31:145-58.

74. Blum RA, D’Andrea DT, Florentino BM, et al. Increased gastric pH and the bioavailability of fluconazole and ketoconazole. Ann Intern Med 1991;114:755-7.

75. Andreana A, Aggarwal S, Gollapudi S, Wien D, Tsuruo T, Gupta S. Abnormal expression of a 170-kilodalton P-glycoprotein encoded by MDRI gene, a metabolically active efflux pump, in CD4+ and CD8+ T cells from patients with human immunodeficiency virus type 1 infection. AIDS Res Hum Retrovirus 1996;12:1457-62.

76. Kim RB, Fromm MF, Wandel C, et al. The drug transporter Pglycoproteon limits oral absorption and brain entry of HIV-1 protease inhibitors. J Clin Invest 1998;101:289-94.

77. Schuetz EG, Beck WT, Schuetz JD. Modulators and substrates for P-glycoprotein and cytochrome P450A coordinately upregulate these proteins in human colon carcinoma cells. Mol Pharmacol 1996;49:311-8.

78. Lee BL, Wong D, Benowitz NL, Sullam PM. Altered patterns of drug metabolism in patients with acquired immunodeficiency syndrome. Clin Pharmacol Ther 1993;53:529-35.

79. O’Neil WM, Gilfix BM, DiGirolamo A, Tsoukas CM, Wainer IW. N-Acetylation among HIV positive and AIDS patients: when is fast, fast and slow, slow? Clin Pharmacol Ther 1997;62:261-71.

80. Kaufmann GR, Wenk M, Taeschner W, et al. N-Acetyltransferase 2 polymorphism in patients infected with human immunodeficiency virus. Clin Pharmacol Ther 1996;60:62-7.

81. Acocella G, Nonis A, Perna G, Patane E, Gialdroni-Grassi G, Grassi C. comparative bioavailability of isoniazid, rifampin, and pyrazinamide administered in free combination and in a fixed triple formulation designed for daily use in antituberculosis chemotherapy. Am Rev Respir Dis 1988;138:886-90.

82. Ellard GA, Ellard DR, Allen BW, et al. The bioavailability of isoniazid, rifampin, and pyrazinamide in two commercially available combined formulations designed for use in the shortcourse treatment of tuberculosis. Am Rev Respir Dis 1986;133:1076-80.

83. Larsson KI, Berning SE, Peloquin CA. Is monitoring of drug therapy in patients wih cystic fibrosis and mycobacterial disease necessary? [abstract]. Am J Respir Crit Care Med 1997;155:A642.

84. Sahai J, Gallicano K, Swick L, et al. Reduced plasma concentrations of antituberculosis drugs in patients with HIV infection. Ann Intern Med 1997;127:289-93.

85. Peloquin CA, Nitta AT, Burman WJ, et al. Low antituberculosisdrug concentrations in patients with AIDS. Ann Pharmacother 1996;30:919-25.

86. Berning SE, Huitt GA, Iseman MD, Peloquin CA. Malabsorption of antituberculosis medications by a patient with AIDS [letter]. N Engl J Med 1992;327:1817-8.

87. Patel KB, Belmonte R, Crowe HM. Drug malabsorption and resistant tuberculosis in HIV-infected patients [letter]. N Engl J Med 1995;332:336-7.

88. Peloquin CA, MacPhee AA, Berning SE. Malabsorption of antimycobacterial medications [letter]. N Engl J Med 1993;329:1122-3.

89. Gordon SM, Horsburgh CR Jr, Peloquin CA, et al. Low serum levels of oral antimycobacterial agents in patients with disseminated Mycobacterium avium complex disease. J Infect Dis 1993;168:1559-62.

90. Colborn D, Lewis R, Narang P. HIV disease severity does not influence rifabutin absorption [abstract no. A-42]. In: Program and abstracts of the 34th Interscience Conference on Antimicrobial Agents and Chemotherapy. Washington, DC: American Society for Microbiology, 1994:39.

91. Gatti G, Papa P, Torre D, et al. Population pharmacokinetic analysis of rifabutin in HIV-infected patients [abstract no. A-10]. In: Program and abstracts of the 37th Interscience Conference on Antimicrobial Agents and Chemotherapy. Washington, DC: American Society for Microbiology, 1997:2.

92. Owens RC Jr, Keung AC, Gardner S, et al. Pharmacokinetic and food effect evaluation of rifapentine in subjects seropositive for the human immunodeficiency virus [abstract no. A-2]. In: Program and abstracts of the 37th Interscience Conference on Antimicrobial Agents and Chemotherapy. Washington, DC: American Society for Microbiology, 1997:1.

93. Owens RC, Pate KB, Benevicius MA, Quintiliani R, Nightingale CH, Nicolau DP. Oral bioavailability and pharmacokinetics of ciprofloxacin in patients with AIDS. Antimicrob Agents Chemother 1997;41:1508-11.

94. Ehrenpreis ED, Ganger DR, Kochvar GT, Patterson BK, Craig RM. D-xilose malabsorption: characteristic finding in patients with the AIDS wasting syndrome and chronic diarrhea. J Acquir Immune Defic Syndr 1992;5:1047-50.

95. Kotler DP, Francisco A, Clayton D, Scholes JV, Orenstein JM. Small intestinal injury and parasitic diseases in AIDS. Ann Intern Med 1990;113:444-9.

96. Kotler DP, Giang TT, Thiim M, Nataro JP, Sordillo EM, Orenstein JM. Chronic bacterial enteropathy in patients with AIDS. J Infect Dis 1995;171:552-8.

97. Peloquin CA. Using therapeutic drug monitoring to dose the antimycobacterial drugs. Clin Chest Med 1997;18:79-87.

98. El-Sadr W, Perlman DC, Matts JP, et al. The evaluation of an intensive intermittent induction regimen and short course duration of treatment for HIV-related pulmonary tuberculosis. Clin Infect Dis 1998;26:1148-58.

99. Peloquin CA, Henshaw TL, Huitt GA, Berning SE, Nitta AT, James GT. Pharmarcokinetic evaluation of p-aminosalicylic acid granules. Pharmacotherapy 1994;14:40-6.

100. Lederberger B, Bettex JD, Joos B, Flepp M, Luthy R. Effect of standard breakfast on drug absorption and multiple-dose pharmacokinetics of ciprofloxacin. Antimicrob Agents Chemother 1985;27:350-2.

101. Sahai J, Gallicano K, Oliveras L, Khaliq S, Hawley-Foss N, Garber G. Cations in didanosine tablet reduce ciprofloxacin bioavailability. Clin Pharmacol Ther 1993;53:292-7.

102. Polk RE, Healy DP, Sahai J, Drwal L, Racht E. Effect of ferrous sulfate and multivitamins with zinc on absorption of ciprofloxacin in normal volunteers. Antimicrob Agents Chemother 1989;33:1841-4.

103. Peloquin CA, Bulpitt AE, Jaresko GS, Jelliffe RW, Nix DE. Effect of food and antacids on the pharmacokinetics (PK) of ehambutol (EMB) and pyrazinamida (PZA) [abstract no. A-3]. In: Program and abstracts of the 37th Interscience Conference on Antimicrobial Agents and Chemotherapy. Washington, DC: American Society for Microbiology, 1997:1.

104. Ameer B, Polk RE, Kline BJ, Grisafe JP. Effect of food on ethambutol absorption. Clin Pharmacy 1982;1:156-8.

105. Mattila MJ, Linnoila M, Seppala T, Koskinen R. Effect of aluminum hydroxide and glycopyrronium on the absorption of ethambutol and alcohol in man. Br J Clin Pharmacol 1978;5:161-6.

106. Peloquin CA, Namdar R, Nix DE. Effect of food and antacids on the pharmacokinetics (PK) on isoniazid (INH) and rifampin ((RIF) [abstract]. Am J Resp Crit Care Med 1998;157:A493.

107. Melander A, Danielson K, Hanson A, et al. Reduction of isoniazid bioavailability in normal men by concomitant intake of food. Acta Med Scand 1976;200:93-7.

108. Zent C, Smith P. Study of the effect of concomitant food on the bioavailability of rifampicin, isoniazid, and pyrazinamide. Tubercle Lung Dis 1995;76:109-13.

109. Gallicano K, Sahai J, Zaror-Behrens G, Pakuts A. Effect of antacids in didanosine tablet on bioavailability of isoniazid. Antimicrob Agents Chemother 1994;38:894-7.

110. Hurwitz A, Schlozman DL. Effects of antacids on gastrointestinal absorption of isoniazid in rats and man. Am Rev Respir Dis 1974;109:41-7.

111. Mannisto P, Mantyla R, Klinge E, Nykanen S, Koponen A, Lamminsivu U. Influence of various diets on the bioavailability of isoniazid. J Antimicrob Chemother 1982;10:427-34.

112. Lenhto P, Kinvisto KT. Effect of sucralfate on absorption of norfloxacin and ofloxacin. Antimicrob Agents Chemother 1994;38:248-51.

113. Lenhto P, Kinvisto KT, Neuvonen PJ. The effect of ferrous sulfate on the absorption of norfloxacin, ciprofloxacin, and ofloxacin. Br J Clin Pharmacol 1994;37:82-5.

114. Narang PK, Lewis RC, Bianchine JR. Rifabutin absorption in humans: relative bioavailability and food effect. Clin Pharmacol Ther 1992;52:335-41.

115. Sahai J, Narang PK, Hawley-Foss N, Li RC, Kamal M, Cameron DW. A phase I evaluation of concomitant rifabutin and didanosine in symptomatic HIV-infected patients. J Acquir Immun Defic Syndr 1995;9:274-9.

116. Siegler DI, Bryant M, Burley DM, Citron KM, Standen SM. Effect pd meals on rifampicin absorption. Lancet 1974;2:197-8.

117. Purohit SD, Johri SC, Mehta YR, Bhatnagar M. Ranitidinerifampin interaction. J Assoc Physicians India 1992;40:308-10.

118. Khalil SAH, El-Khordagui LK, El-Gholmy Z. Effect of antacids on oral absorption of rifampin. International Journal of Pharmaceutics 1984;20:99-106.

119. Rao KVN, Kailisam S, Menon NK, Radharrishna S. Inactivation of isoniazid by condensation in a syrup preparation. Indian J Med Res 1971;50:1343-53.

120. Lee BL, Tauber MG, Chambers HF, Gambertoglio J, Delahunty T. The effect of zalcitabine on the pharmacokinetics of isoniazid in HIV-infected patients [abstract no. A4]. In: Program and abstracts of the 34th Interscience Conference on Antimicrobial Agents and Chemotherapy. Washington, DC: American Society for Microbiology, 1994:3.

121. Chan SL, Yew WW, Porter JHD, et al. Comparison of Chinese and Western rifapentines and improvement by prior taking of various meals. Int J Antimicrob Agents 1994;3:267-74.

122. Perucca E, Grimaldi R, Frigo GM, Sardi A, Monig H, Ohnhaus EE. Comparative effects of rifabutin and rifampicin on hepatic microsomal enzyme activity in normal subjects. Eur J Clin Pharmacol 1988;34:595-9.

123. Durand DV, Hampden C, Boobis AR, Park BK, Davies DS. Induction of mixed function oxidase activity in man by rifapentine (MDL 473), a long-acting rifamycin derivative. Br J Clin Pharmacol 1986;21:1-7.

124. Indinavir pharmacokinetics study group. Indinavir (MK 639) drug interactions studies [abstract no MoB174]. In: Program and abstracts of the XI International AIDS Conference. Vancouver. XI International Conference on AIDS Society, 1996:18.

125. Sahai J, Stewart F, Swick L, et al. Rifabutin reduces saquinavir plasma levels in HIV-infected patients [abstract no A27]. In: Program and abstracts of the 36th Interscience Conference on Antimicrobial Agents and Chemotherapy. Washington, DC: American Society for Microbiology, 1996:6.

126. Polk RE, Osrael DS, Patron R, et al. Pharmacokinetic interaction between 141W94 and rifabutin and rifampin after multiple doseadministration [abstract no 340]. In: Program and abstracts of the 5th Conference on Retroviruses and Opportunistic Infections. Alexandria, VA: Foundation for Retrovirology and Human Health, 1998:143.

127. Product insert: Norvir. Abbott Laboratories, 1997.

128. Sadler B, Gillotin C, Chittick GE, Symonds WT. Pharmacokinetic drug interactions with amprenavir [abstract no 12389]. In Conference record of the 12th World AIDS Conference. Geneva: Marathon Multimedia, 1998:91.

129. Borin MT, Chambers JH, Carel BJ, Gagnon S, Freimuth WW. Pharmacokinetic study of the interaction between rifampin and delavirdine mesylate. Clin Pharmacol Ther 1997;61:544-53.

130. Stein DS, Fish DG, Bilello JA, Preston SL, Martineau GL, Drusano GL. A 24-week open-label Phase I/II evaluation of the HIV protease inhibitor MK-639 (indinavir). AIDS 1996;10:485- 92.

131. Zhang K, Wu E, Patick A, et al. Plasma metabolites of nelfinavir, a potent HIV protease inhibitor in HIV-positive patients: quantitation by LC-MS/MS and antiviral activities [abstract no 128]. Presented at the 6th European International Society for Study of Xwnobiotics Meeting (Gottenberg, Sweden). 1997.

132. Iatsimirskaia E, Tulebaev S, Storozhuk E, et al. Metabolism of rifabutin in human enterocyte and liver microsomes: kinetic parameters, identification of enzyme systems, and drug interactions with macrolides and antifungal agents. Clin Pharmacol Ther 1997;61:554-62.

133. Acocella G. Clinical pharmacokinetics of rifampicin. Clin Pharmacokinet 1978;3:108-27.

134. Sun E, Heath-Chiozzi M, Cameron DW, et al. Concurrent ritonavir and rifabutin increases risk of rifabutin-associated adverse events [abstract no MoB171]. In: Program and abstracts of the XI International AIDS Conference. Vancouver. XI International Conference on AIDS Society, 1996:18.

135. Torseth J, Bhatia G, Harkonen S, et al. Evaluation of the antiviral effect of rifabutin in AIDS- related complex. J Infect Dis 1989;159:1115-8.

136. Griffith DE, Brown BA, Girard WM, Wallace RJ Jr. Adverse eventsassociated with high-dose rifabutin in macrolidecontaining regimens for the treatment of Mycobacterium avium lung disease. Clin Infect Dis 1995;21:594-8.

137. Shafran SD, Singer J, Zarowny DP, et al. A comparison of two regimens for the treatment of Mycobacterium avium complex bacteremia in AIDS: rifabutin, ethambutol, and clarithromycin versus rifampin, ethambutol, clofazimine, and ciprofloxacin. N Engl J Med 1996;335:377-83.

138. Benson CA. Critical drug interactions with agents used for prophylaxis and treatment of Mycobacterium avium complex infection. Am J Med 1997;102:32-6.

139. Stretcher BN, Pesce AJ, Frame PT, Greenberg KA, Stein DS. Correlates of zidovudine phosphorylation with markers of HIV disease progression and drug toxicity. AIDS 1994;8:763-9.

140. Barry MG, Khoo SH, Veal GJ, et al. The effect of zidovudine dose on the formation of intracellular phosphorylation metabolites. AIDS 1996;10:1361-7.

141. Stretcher BN, Pesce AJ, Frame PT, Stein DS. Pharmacokinetics of zidovudine phosphorylation in peripheral blood mononuclear cells from patients infected with human immunodeficiency virus. Antimicrob Agents Chemother 1994;38:1541-7.

142. Haumont M, Magdalou J, Lafaurie C, Ziegler JM, Siest G, Colin JN. Phenobarbital inducible UDP-glucoronosyltransferase is responsible for glucoronidation of 3’-azido-3’-deoxythymidine: characterization of the enzyme in human and rat liver microsomes. Arch Biochem Biophys 1990;281:264-70.

143. Oesch F, Arand M, Strolin-Bendetti M, Castelli MG, Dostert P. Inducing properties of rifampin and rifabutin for selected enzyme activities of the cytochrome P-450 and UDP- glucoronosyltransferase superfamilies in female rat liver. J Antimicrob Chemother 1996:37:1111-9.

144. Cato A, Qian J, Hsu A, Levy B, Leonard J, Granneman R. Multidose pharmacokinetics of ritonavir and zidovudine in human immunodeficiency virus-infected patients. Antimicrob Agents Chemother 1998;42:1788-93.

145. Gallicano K, Sahai J, Swick L, Seguin I, Pakuts A, Cameron DW. Effect of rifabutin on the pharmacokinetics of zidovudine in patients infected with human immunodeficiency virus. Clin Infect Dis 1995;21:1008-11.

146. Narag P, Sale M. population-based assessment of rifabutin effect on zidovudine disposition in AIDS patients. Clin Pharmacol Ther 1993;53:219.

147. Ravitch JR, Bryant BJ, Reese MJ, et al. In vivo and in vitro studies of the potential for drug interactions involving the antiretroviral 1592 in humans [abstract no 634. In: Program and abstracts of the 5th Conference on Retroviruses and Opportunistic Infections. Alexandria, VA: Foundation for Retrovirology and Human Health, 1998:199.

148. Product insert: Viramune, Roxane Laboratories, 1997.

149. Borin MT; Chambers JH, Carel BJ, Freimuth WW, Aksentijevich S, Piergies AA. Pharmacokinetics study of the interaction between rifabutin and delavirdine mesylate in HIV-1 infected patients. Antiviral Res 1997;35:53-63.

150. Cox SR, Herman BD, Batta DH, Carel BJ, Carberry PA. Delavirdine and rifabutin: pharmacokinetic evaluation in HIV- 1 patients with concentration-targeting of delavirdine [abstract no 344]. In: Program and abstracts of the of the 5th Conference on Retroviruses and Opportunistic Infections. Alexandria, VA: Foundation for Retrovirology and Human Health, 1998:144.

151. Benedek IH, Joshi A, Fiske WD, et al. Pharmacokinetic interaction between efavirenz and rifampin in healthy volunteers [abstract no 42280]. In: Conference record of the 12th World AIDS Conference. Geneva: Marathon Multimedia, 1998:829.

152. Benedek IH, Fiske WD, White SJ, Stevenson D, Joseph JL, Kornhauser DM. Pharmacokinetic interaction between multiple doses of efavirenz and rifabutin in healthy volunteers [abstract]. Clin Infect Dis 1998;27:1008.

153. Jenner PJ, Ellard GA. High performance liquid chromatpgraphic determination of ethionamide and prothionamide in body fluids. Journal of Chromatography-Biomedical Applications 1981;225:245-51.

154. Mannheimer SB, Medard F, El-Sadr W. The use of protease inhibitors in persons with HIV and tuberculosis [abstract]. Am J Respir Crit Care Med 1998;157:A573.

155. Gazzard B, Moyle G, the BHIVA Guidelines Writing Committee. 1998 revisión to the British HIV Association guidelines antiretroviral treatment of HIV seropositive individuals. Lancet 1998;352:314-6.

156. Morris L, Martin DJ, Sacks L, et al. Persistent elevation of HIV viralload during therapy for tuberculosis [abstract no 259]. In: Program and abstracts of the 5th Conference on Retroviruses and Opportunistic Infections. Alexandria, VA: Foundation for Retrovirology and Human Health, 1998:85.

157. Raboud J, Montaner JSG, Rae S, et al. Patients with higher baseline pVL are less likely to have a virologic response in a meta-analysis of two trials of ZDV/ddI vs ZDV/ddI/NVP [abstract no 12361]. In: Conference record of the 12th World AIDS Conference. Geneva: Marathon Multimedia, 1998:85.

158. Staszewski S, Morales-Ramírez J, Flanigan T, et al. A phase II, multicenter, randomized study to compare activity and tolerability of efavirenz (EFV) + indinavir (IND), versus EFV + zidovudine (ZDV) + lamivudine (3TC), versus IDV + ZDV + 3TC at 24 weeks [abstract no 22336]. In: Conference record of the 12th World AIDS Conference. Geneva: Marathon Multimedia, 1998:330.